Health
Drug Pricing Reform Failure is Unacceptable
Drug Prices
Drug Pricing Reform Failure is Unacceptable
Op-Ed

Part 3: After a Groundswell of Success in 2021, Stage is Set for Broader Rx Reform in 2022
Drug Prices
Part 3: After a Groundswell of Success in 2021, Stage is Set for Broader Rx Reform in 2022
Drug Affordability

Part 2: In Quest to Lower Rx Prices, States Deploy New Tools
Drug Prices
Part 2: In Quest to Lower Rx Prices, States Deploy New Tools
Drug Affordability

Part 1: As Congress Debates Lowering Drug Prices, States Waste No Time
Drug Prices
Part 1: As Congress Debates Lowering Drug Prices, States Waste No Time
Drug Affordability

Protecting Patients From the Cost of Surprise Billing is Not Finished
Commercial Sector Prices
Protecting Patients From the Cost of Surprise Billing is Not Finished

FDA's Pfizer Vaccine Approval is Proof that Public-Private Partnerships Work
Drug Prices
FDA’s Pfizer Vaccine Approval is Proof that Public-Private Partnerships Work

Any Public Option Design Must Lower Health Care Costs
Commercial Sector Prices
Any Public Option Design Must Lower Health Care Costs

5 Things to Watch for in the Medicare Trustees’ Report
Medicare Sustainability
5 Things to Watch for in the Medicare Trustees’ Report

Biden Takes Aim at Drug Prices with Executive Order. Does it Go Far Enough?
Drug Prices
Biden Takes Aim at Drug Prices with Executive Order. Does it Go Far Enough?

New Poll: Majority of Voters Want Congress To Take Action To Lower Health Care Prices
Commercial Sector Prices
New Poll: Majority of Voters Want Congress To Take Action To Lower Health Care Prices
Video Series: Health Care Prices

MACPAC Recommends Policies To Reduce Spending on High Cost Specialty Drugs in the Medicaid Program
Drug Prices
MACPAC Recommends Policies To Reduce Spending on High Cost Specialty Drugs in the Medicaid Program

'We Have a Problem': New Alzheimer’s Treatment Reflects Dysfunctional U.S. Drug Market
Drug Prices
‘We Have a Problem’: New Alzheimer’s Treatment Reflects Dysfunctional U.S. Drug Market

Part 2: In No Surprises Act, Arbitration Design Is Key to Realizing Expected Savings
Commercial Sector Prices
Part 2: In No Surprises Act, Arbitration Design Is Key to Realizing Expected Savings

Part 1: Fulfilling the Promises of the Surprise Billing Ban
Commercial Sector Prices
Part 1: Fulfilling the Promises of the Surprise Billing Ban

‘It’s Just Simply the Cost Per Dose That Americans Are Being Charged More For’
Drug Prices
‘It’s Just Simply the Cost Per Dose That Americans Are Being Charged More For’
Q&A

Congress Grills Major Drug Manufacturer on Anticompetitive Tactics and Price Gouging
Drug Prices
Congress Grills Major Drug Manufacturer on Anticompetitive Tactics and Price Gouging

COVID-19 Vaccines are Evidence that Government Intervention Works
Drug Prices
COVID-19 Vaccines are Evidence that Government Intervention Works
Op-Ed

Policies Take Aim at Rising Health Care Costs Hurting Families, Employers and Taxpayers
Commercial Sector Prices
Policies Take Aim at Rising Health Care Costs Hurting Families, Employers and Taxpayers

President Biden Called on Congress to Lower Drug Prices. What’s Next?
Drug Prices
President Biden Called on Congress to Lower Drug Prices. What’s Next?

New Laws Take Aim at Drug Prices, But Stronger Action Needed
Drug Prices
New Laws Take Aim at Drug Prices, But Stronger Action Needed
The Opioid Epidemic
Richard Frank: COVID Dollars, Best Practices Arm Communities with New Weapons Against Drug-Overdose Scourge
Op-Ed

About Us
We strive to maximize opportunity and minimize injustice by investing in systemic solutions that will outlast our funding.